BioArctic AB, a developer of the recently approved Alzheimer’s disease drug Leqembi, has recruited Anders Martin-Löf as chief financial officer effective 1 June. He will succeed Jan Mattsson who will become vice president of finance. Mr Martin-Löf will join from A3P Biomedical AB, a diagnostics company, where he is CFO. He has also been CFO at RaySearch Laboratories AB which develops software for radiation therapies. Mr Martin-Löf holds a Master of Science degree in engineering physics from the Royal Institute of Technology and a Bachelor of Science in business administration and economics from Stockholm University, both in Sweden.
BioArctic announced the appointment on 28 February 2023
Copyright 2023 Evernow Publishing Ltd